GRAIL (NASDAQ:GRAL) Stock Jumps 6.9% – What’s Next?

GRAIL, Inc. (NASDAQ:GRAL)’s share price was up 6.9% during mid-day trading on Thursday. The stock traded as high as $113.09 and last traded at $115.9690. Approximately 510,514 shares changed hands during mid-day trading, a decline of 46% from the average session volume of 948,330 shares. The stock had previously closed at $108.52.

Key Stories Impacting GRAIL

Here are the key news stories impacting GRAIL this week:

• Positive Sentiment: FDA advisers recommended approval of Galleri after supporting its safety and narrowly endorsing its efficacy. A final FDA ruling is expected in the coming months; approval could expand insurance coverage, market access and adoption of GRAIL’s primary product. Reuters FDA panel article
• Positive Sentiment: The regulatory catalyst has driven a substantial weekly rally and helped GRAL reach a new 52-week high, as investors price in the potential commercial impact of FDA approval. Seeking Alpha FDA panel article
• Neutral Sentiment: Analyst sentiment remains cautious following the rally. Mizuho raised its price target to $100 from $65 but maintained a neutral rating, while RBC Capital reiterated its hold rating. These targets remain below recent trading levels, suggesting analysts view much of the FDA optimism as already reflected in the valuation. RBC Capital hold rating
• Negative Sentiment: The panel’s narrow efficacy endorsement leaves regulatory and adoption risks unresolved. Galleri’s commercial opportunity depends on final FDA approval, physician and insurer acceptance, and evidence that the test improves patient outcomes. Yahoo Finance FDA panel valuation article
• Negative Sentiment: Insider selling may weigh modestly on sentiment: CEO Joshua Ofman sold 61,452 shares and CFO Aaron Freidin sold 4,100 shares under pre-arranged Rule 10b5-1 plans. The transactions are less concerning than discretionary sales but can add pressure after the sharp advance. GRAIL insider sale article

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on GRAL shares. The Goldman Sachs Group initiated coverage on shares of GRAIL in a report on Friday, June 5th. They set a “neutral” rating and a $60.00 price objective for the company. Royal Bank Of Canada assumed coverage on shares of GRAIL in a research note on Thursday, September 17th. They issued a “sector perform” rating and a $84.00 target price on the stock. Mizuho increased their price target on shares of GRAIL from $65.00 to $100.00 and gave the stock a “neutral” rating in a research report on Friday. TD Cowen restated a “buy” rating on shares of GRAIL in a research note on Thursday. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Friday, July 17th. Five equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, GRAIL currently has a consensus rating of “Hold” and a consensus target price of $78.60.

GRAIL Stock Performance

The stock has a market cap of $5.67 billion, a price-to-earnings ratio of -13.01 and a beta of 3.25. The firm’s 50-day simple moving average is $78.42 and its two-hundred day simple moving average is $65.68.

GRAIL (NASDAQ:GRAL) last announced its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. The company had revenue of $44.69 million for the quarter, compared to analyst estimates of $42.39 million. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. Equities research analysts expect that GRAIL, Inc. will post -10.41 earnings per share for the current fiscal year.

Insider Buying and Selling at GRAIL

In other GRAIL news, CEO Joshua Ofman sold 61,452 shares of the company’s stock in a transaction on Monday, September 21st. The stock was sold at an average price of $97.74, for a total transaction of $6,006,318.48. Following the transaction, the chief executive officer owned 362,271 shares of the company’s stock, valued at approximately $35,408,367.54. This represents a 14.50% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Freidin sold 7,900 shares of the stock in a transaction on Thursday, August 27th. The shares were sold at an average price of $85.01, for a total value of $671,579.00. Following the completion of the transaction, the chief financial officer owned 253,083 shares in the company, valued at $21,514,585.83. The trade was a 3.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 78,452 shares of company stock worth $7,485,691. Company insiders own 1.83% of the company’s stock.

Hedge Funds Weigh In On GRAIL

Several hedge funds have recently added to or reduced their stakes in GRAL. BlackRock Inc. raised its holdings in GRAIL by 20.5% during the 2nd quarter. BlackRock Inc. now owns 3,577,075 shares of the company’s stock worth $244,207,000 after purchasing an additional 608,539 shares during the last quarter. Baker BROS. Advisors LP grew its position in shares of GRAIL by 27.9% during the 4th quarter. Baker BROS. Advisors LP now owns 2,085,333 shares of the company’s stock worth $178,484,000 after buying an additional 455,208 shares during the period. State Street Corp grew its position in shares of GRAIL by 26.1% during the 2nd quarter. State Street Corp now owns 2,385,514 shares of the company’s stock worth $162,859,000 after buying an additional 493,621 shares during the period. Primecap Management Co. CA bought a new stake in shares of GRAIL during the second quarter worth approximately $148,836,000. Finally, Geode Capital Management LLC raised its stake in shares of GRAIL by 9.8% during the fourth quarter. Geode Capital Management LLC now owns 801,503 shares of the company’s stock worth $68,609,000 after buying an additional 71,253 shares during the last quarter.

GRAIL Company Profile

GRAIL, Inc is a healthcare company focused on developing blood-based tests for the early detection of cancer. Its technology uses genomic and epigenomic signals, including patterns of DNA methylation, to identify signals associated with multiple cancer types from a single blood sample.

The company’s primary product is Galleri, a prescription blood test designed to screen for signals of more than 50 types of cancer, including cancers that currently lack recommended screening methods. Galleri is intended to complement, not replace, guideline-recommended cancer screenings, and a positive result requires follow-up diagnostic testing to determine whether cancer is present and where it may be located.

GRAIL was founded in 2016 as a subsidiary of Illumina and became an independent publicly traded company following its separation from Illumina in 2021.